Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05RSS
|
|||
| Former ID |
DIB012172
|
|||
| Drug Name |
PF-03772304
|
|||
| Synonyms |
MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1] | |
| Company |
Wyeth Research
|
|||
| Structure |
 |
Download2D MOL |
||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.